Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Cancer Chemotherapy and Pharmacology · 2023
DOI: 10.1007/s00280-023-04517-8 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Stefanie L Groenland und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherl…. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Dabrafenib and trametinib are currently administered at fixed doses, at which interpatient variability in exposure is high. The aim of this study was to investigate whether drug exposure is related to efficacy and toxicity in a real-life cohort of melanoma patients treated with dabrafenib plus trametinib. PATIENTS AND METHODS: An observational study was performed in which pharmacokinetic samples were collected as routine care. Using estimated dabrafenib Area Under the concentration-time Curve and trametinib trough concentrations (Cmin), univariable and multivariable exposure-response analyses were performed. RESULTS: In total, 140 patients were included. Dabrafenib exposure was not related to either progression-free survival (PFS) or overall survival (OS). Trametinib exposure was related to survival, with Cmin ≥ 15.6 ng/mL being identified as the optimal threshold. Median OS was significantly longer in patients with trametinib Cmin ≥ 15.6 ng/mL (22.8 vs. 12.6 months, P = 0.003), with a multivariable hazard ratio of 0.55 (95% CI 0.36-0.85, P = 0.007). Median PFS in patients with trametinib Cmin levels ≥ 15.6 ng/mL (37%) was 10.9 months, compared with 6.0 months for those with Cmin below this threshold (P = 0.06). Multivariable analysis resulted in a hazard ratio of 0.70 (95% CI 0.47-1.05, P = 0.082). Exposure to dabrafenib and trametinib was not related to clinically relevant toxicities. CONCLUSIONS: Overall survival of metastasized melanoma patients with trametinib Cmin levels ≥ 15.6 ng/mL is ten months longer compared to patients with Cmin below this threshold. This would theoretically provide a rationale for therapeutic drug monitoring of trametinib. Although a high proportion of patients are underexposed, there is very little scope for dose increments due to the risk of serious toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.groenland@nki.nl.
- Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Zitieren
APA
Groenland, S. L., Janssen, J. M., Nijenhuis, C. M., de Vries, N., Rosing, H., Wilgenhof, S., van Thienen, J. V., Haanen, J. B. A. G., Blank, C. U., Beijnen, J. H., Huitema, A. D. R., & Steeghs, N. (2023). Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04517-8
Vancouver
Groenland SL, Janssen JM, Nijenhuis CM, de Vries N, Rosing H, Wilgenhof S, et al. Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04517-8
BibTeX
@article{Groenland2023,
author = {Groenland, Stefanie L and Janssen, J M and Nijenhuis, C M and de Vries, N and Rosing, H and Wilgenhof, S and van Thienen, J V and Haanen, J B A G and Blank, C U and Beijnen, J H and Huitema, A D R and Steeghs, N},
title = {Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2023},
doi = {10.1007/s00280-023-04517-8}
}
EUVIMED